366 related articles for article (PubMed ID: 19281429)
1. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
[TBL] [Abstract][Full Text] [Related]
2. Risk of second primary breast cancer after radioactive iodine treatment in thyroid cancer: a systematic review and meta-analysis.
Zhang Y; Liang J; Li H; Cong H; Lin Y
Nucl Med Commun; 2016 Feb; 37(2):110-5. PubMed ID: 26513055
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer.
Yu CY; Saeed O; Goldberg AS; Farooq S; Fazelzad R; Goldstein DP; Tsang RW; Brierley JD; Ezzat S; Thabane L; Goldsmith CH; Sawka AM
Thyroid; 2018 Dec; 28(12):1662-1673. PubMed ID: 30370820
[No Abstract] [Full Text] [Related]
4. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
5. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
6. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
7. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis.
Subramanian S; Goldstein DP; Parlea L; Thabane L; Ezzat S; Ibrahim-Zada I; Straus S; Brierley JD; Tsang RW; Gafni A; Rotstein L; Sawka AM
Thyroid; 2007 Dec; 17(12):1277-88. PubMed ID: 18020916
[TBL] [Abstract][Full Text] [Related]
8. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
Reinecke MJ; Ahlers G; Burchert A; Eilsberger F; Flux GD; Marlowe RJ; Mueller HH; Reiners C; Rohde F; van Santen HM; Luster M
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386
[TBL] [Abstract][Full Text] [Related]
9. Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.
Mei X; Yao X; Feng F; Cheng W; Wang H
BMC Cancer; 2021 May; 21(1):543. PubMed ID: 33980182
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
11. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
Pasqual E; Schonfeld S; Morton LM; Villoing D; Lee C; Berrington de Gonzalez A; Kitahara CM
J Clin Oncol; 2022 May; 40(13):1439-1449. PubMed ID: 35044839
[TBL] [Abstract][Full Text] [Related]
12. Weighing shadows: can meta-analysis help define the risk-benefit ratio of RAI treatment for low-risk thyroid cancer patients?
Schneider AB; Viana MA; Ron E
Thyroid; 2009 May; 19(5):435-6. PubMed ID: 19415992
[No Abstract] [Full Text] [Related]
13. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
Marti JL; Jain KS; Morris LG
Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
[TBL] [Abstract][Full Text] [Related]
14. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study.
Kim M; Kim H; Park S; Joo J; Kim IJ; Kim BH
Eur J Endocrinol; 2022 Apr; 186(5):561-571. PubMed ID: 35286279
[TBL] [Abstract][Full Text] [Related]
16. Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?
Souza MC; Momesso DP; Vaisman F; Vieira Neto L; Martins RA; Corbo R; Vaisman M
Arch Endocrinol Metab; 2016 Feb; 60(1):9-15. PubMed ID: 26222230
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL
Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770
[TBL] [Abstract][Full Text] [Related]
18. Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Systematic Review and Meta-analysis.
Shim SR; Kitahara CM; Cha ES; Kim SJ; Bang YJ; Lee WJ
JAMA Netw Open; 2021 Sep; 4(9):e2125072. PubMed ID: 34533571
[TBL] [Abstract][Full Text] [Related]
19. Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis.
Nappi C; Klain M; Cantoni V; Green R; Piscopo L; Volpe F; Maurea S; Petretta M; Cuocolo A
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1630-1639. PubMed ID: 34820683
[TBL] [Abstract][Full Text] [Related]
20. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors.
Sawka AM; Lakra DC; Lea J; Alshehri B; Tsang RW; Brierley JD; Straus S; Thabane L; Gafni A; Ezzat S; George SR; Goldstein DP
Clin Endocrinol (Oxf); 2008 Sep; 69(3):479-90. PubMed ID: 18284643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
